N/A
Completed N=84
Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
Source: ClinicalTrials.gov NCT01137110 ↗Enrolled (actual)
84
Serious AEs
4.8%
Results posted
Jul 2019
Primary outcomePrimary: In-hospital Seizures — 3; 1 Participants
Summary
Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY In-hospital Seizures |
3; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Age >18 years of age
- Diagnosis of spontaneous SAH
Exclusion Criteria
- SAH secondary to trauma or arteriovenous malformation
- Early death (defined as death within 3 days of presentation)
- Known allergy to levetiracetam
- Know seizure history on chronic AEDs
- Pregnancy
- Current incarceration
Data sourced from ClinicalTrials.gov (NCT01137110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.